Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities (2010 - 2026)

Jazz Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $123.1 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 172.84% year-over-year to $123.1 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 200.48% YoY), while the FY2025 annual figure was -$1.5 billion, down 197.11% from the prior year.
• Cash from Investing Activities was $123.1 million for Q1 2026 at Jazz Pharmaceuticals, up from -$372.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $214.1 million in Q3 2024 to a low of -$641.0 million in Q2 2025.
• Historically, Cash from Investing Activities has averaged -$147.3 million across 5 years, with a median of -$169.0 million in 2025.
• Biggest YoY gain for Cash from Investing Activities was 222.83% in 2024; the steepest drop was 5538.82% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$324.4 million in 2022, then jumped by 131.38% to $101.8 million in 2023, then sank by 289.87% to -$193.3 million in 2024, then plunged by 92.54% to -$372.2 million in 2025, then soared by 133.08% to $123.1 million in 2026.
• The last three Cash from Investing Activities figures came in at $123.1 million (Q1 2026), -$372.2 million (Q4 2025), and -$327.8 million (Q3 2025), per Business Quant data.